HEADER RECORD*******LIBRARY HEADER RECORD!!!!!!!000000000000000000000000000000 SAS SAS SASLIB 9.4 X64_SR12 19MAY21:19:09:3119MAY21:19:09:31 HEADER RECORD*******MEMBER HEADER RECORD!!!!!!!000000000000000001600000000140 HEADER RECORD*******DSCRPTR HEADER RECORD!!!!!!!000000000000000000000000000000 SAS TV SASDATA 9.4 X64_SR12 19MAY21:19:09:3119MAY21:19:09:31 Trial Visits HEADER RECORD*******NAMESTR HEADER RECORD!!!!!!!000000000800000000000000000000 STUDYID Study Identifier DOMAIN Domain Abbreviation VISITNUMVisit Number dVISIT Visit Name VISITDY Planned Study Day of Visit |ARMCD Planned Arm Code „hTVSTRL Visit Start Rule ˆ,TVENRL Visit End Rule ðHEADER RECORD*******OBS HEADER RECORD!!!!!!!000000000000000000000000000000 mRNA-1273-P301TVPrevious Screening Â Day of previous inform consent Screen failure mRNA-1273-P301TVAScreening Â Start of Screening Epoch End of Screening Epoch mRNA-1273-P301TVA Visit 1 Day 1 A First day of first study vaccination mRNA-1273-P301TVA0Safety Call Day 8 A€ 7 (+3) days after first study vaccination mRNA-1273-P301TVA@Safety Call Day 15 Að 14 (+3) days after first study vaccination mRNA-1273-P301TVAPSafety Call Day 22 B 21 (+3) days after first study vaccination mRNA-1273-P301TVA`Visit 2 Day 29 B First day of second study vaccination mRNA-1273-P301TVApSafety Call Day 36 B$ 7 (+3) days after last study vaccination mRNA-1273-P301TVA€Safety Call Day 43 B+ 14 (+3) days after last study vaccination mRNA-1273-P301TVASafety Call Day 50 B2 21 (+3) days after last study vaccination mRNA-1273-P301TVA Visit 3 Day 57 B9 28 (-3/+7) days after last study vaccination mRNA-1273-P301TVA°Safety Call Day 85 BU 56 (+/-3) days after last study vaccination mRNA-1273-P301TVAÀSafety Call Day 119 Bw 90 (+/-14) days after last study vaccination mRNA-1273-P301TVAÐSafety Call Day 149 B• 120 (+/-3) days after last study vaccination mRNA-1273-P301TVAàSafety Call Day 179 B³ 150 (+/-3) days after last study vaccination mRNA-1273-P301TVAðVisit 4 Day 209 BÑ 180 (+/-14) days after last study vaccination mRNA-1273-P301TVBSafety Call Day 239 Bï 210 (+/-3) days after last study vaccination mRNA-1273-P301TVBSafety Call Day 269 CÐ 240 (+/-3) days after last study vaccination mRNA-1273-P301TVBSafety Call Day 299 C° 270 (+/-3) days after last study vaccination mRNA-1273-P301TVBSafety Call Day 329 C 300 (+/-3) days after last study vaccination mRNA-1273-P301TVBSafety Call Day 359 Cp 330 (+/-3) days after last study vaccination mRNA-1273-P301TVBVisit 5 Day 394 C 365 (+/-14) days after last study vaccination mRNA-1273-P301TVBSafety Call Day 424 C€ 395 (+/-3) days after last study vaccination mRNA-1273-P301TVBSafety Call Day 454 C` 425 (+/-3) days after last study vaccination mRNA-1273-P301TVBSafety Call Day 484 C@ 455 (+/-3) days after last study vaccination mRNA-1273-P301TVBSafety Call Day 514 C 485 (+/-3) days after last study vaccination mRNA-1273-P301TVBSafety Call Day 544 C" 515 (+/-3) days after last study vaccination mRNA-1273-P301TVBSafety Call Day 604 C%À 575 (+/-3) days after last study vaccination mRNA-1273-P301TVBSafety Call Day 634 C' 605 (+/-3) days after last study vaccination mRNA-1273-P301TVBSafety Call Day 664 C)€ 635 (+/-3) days after last study vaccination mRNA-1273-P301TVBSafety Call Day 694 C+` 665 (+/-3) days after last study vaccination mRNA-1273-P301TVBSafety Call Day 724 C-@ 695 (+/-3) days after last study vaccination mRNA-1273-P301TVB Visit 6 Day 759 C/p 730 (+/-14) days after last study vaccination End of Study mRNA-1273-P301TVB!Illness Visit Day 1 . First day of confirmation of COVID-19 mRNA-1273-P301TVB"Illness Visit Day 3 - Day 21 . 3 (+/-1) days from confirmation of COVID-19 21 (+/-1) days from confirmation of COVID-19mRNA-1273-P301TVB#Convalescence Visit Day 28 . 28 (+7) days from confirmation of COVID-19 mRNA-1273-P301TVB$Participant Decision Visit / OL-D1 . Start of open-label phase mRNA-1273-P301TVB%Safety Call OL-D8 . 7 (+3) days after start of open-label phase for subjects who received mRNA-1273 in open-label phase mRNA-1273-P301TVB&OL-D29 . 29 (-3/+14) days after start of open-label phase for subjects who received mRNA-1273 in open-label phase mRNA-1273-P301TVB'Safety Call OL-D36 . 36 (+3) days after start of open-label phase for subjects who received mRNA-1273 in open-label phase mRNA-1273-P301TVB(OL-D57 . 57 (-3/+14) days after start of open-label phase for subjects who received mRNA-1273 in open-label phase